Latest Research
All publications from the Cancer3.AI database, newest first.
Diagnostic evaluation of renal masses in chronic kidney disease: a clinical and radiologic challenge.
Eusebi L, et al
This narrative review examines the challenge of diagnosing kidney tumors in patients with chronic kidney disease (CKD), a group already at elevated risk for renal cell carcinoma due to long-term dialysis and acquired cystic kidney disease. Structural changes in diseased kidneys and restrictions on iodinated and gadolinium-based contrast agents make standard CT and MRI scans less reliable, leaving many kidney masses without a definitive diagnosis. The authors highlight contrast-enhanced ultrasound (CEUS) as a safe and effective alternative, since its microbubble contrast agents are non-toxic to kidneys and can be used in all CKD patients including those on dialysis. CEUS allows real-time visualization of blood flow within cyst walls, septa, and nodules, enabling clinicians to distinguish truly vascular tumors from benign fluid collections that can mimic cancer on other imaging modalities. The review proposes a structured clinical workflow combining CKD stage, dialysis status, and a CEUS-adapted Bosniak classification system to guide decisions between surveillance, biopsy, or kidney-sparing surgery. These recommendations have direct practical value for radiologists and nephrologists managing a growing population of CKD patients in whom accurate tumor characterization is both critical and technically difficult.
Abdominal radiology (New York)
Source →Perioperative Outcomes from a Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial.
Buckarma E, et al
Researchers conducted the ROBO-CHIP trial, a prospective Phase II study evaluating whether a robotic surgical approach to cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) could improve recovery for patients with low-volume peritoneal metastatic gastric cancer. Eighteen evaluable patients with a peritoneal carcinomatosis index of 7 or lower underwent robotic cytoreduction, gastrectomy, and HIPEC with paclitaxel and cisplatin after completing at least four months of systemic chemotherapy. The primary endpoint of hospital length of stay was just 5 days, and complete cytoreduction was achieved in 100% of patients, with median blood loss of 300 ml and a transfusion rate of 22.2%. The 90-day major complication rate was 38.9% and the readmission rate was 27.8%, with a single reoperation and one death, while HIPEC-related toxicities were minimal. These results compare favorably to historical data on open surgery, suggesting that the robotic approach may offer meaningful benefits in terms of faster recovery and reduced blood loss for a carefully selected patient population. The trial is ongoing to assess long-term cancer control outcomes, which will be critical for determining the full clinical value of this minimally invasive strategy.
Annals of surgical oncology
Source →Comparing incisional hernia risk between single-port and multiport robot-assisted partial nephrectomy: a retrospective analysis.
Valenzi FM, et al
A new retrospective study published in the Journal of Robotic Surgery examined the risk of incisional hernia (IH) — a complication where abdominal tissue pushes through a surgical wound — following two types of robot-assisted partial kidney removal surgery: single-port (SP) and multiport (MP) approaches. Researchers analyzed 279 patients (158 MP, 121 SP) with at least six months of follow-up, finding that IH occurred in only 12 patients overall, with comparable rates between the two groups (4.4% MP vs. 4.1% SP). In the multiport group, risk factors such as previous abdominal surgery and higher body mass index were strongly and independently associated with hernia development, whereas these factors appeared to have less impact in the single-port group. Notably, certain subgroups of single-port patients — particularly those who underwent a retroperitoneal (behind-the-abdomen) approach — showed even lower observed rates of incisional hernia. These findings suggest that single-port robotic partial nephrectomy is a safe alternative to the multiport technique regarding hernia risk, and may offer particular advantages for higher-risk patients such as those with obesity or prior abdominal surgeries.
Journal of robotic surgery
Source →Rational design and evaluation of the sensing mechanism of a europium(III)-based luminescent turn-ON chemosensor for citrate.
Shaw AK, et al
Researchers have designed and evaluated a new luminescent chemical sensor, designated Eu.1, based on a europium(III) metal complex capable of selectively detecting citrate — a key metabolic molecule whose abnormal levels are linked to cancer, kidney stones, liver disease, and neurological disorders. The sensor works by exploiting the natural affinity of europium ions for negatively charged oxygen-rich molecules like citrate, allowing three water molecules in the complex to be displaced when citrate binds, producing a measurable increase in light emission. Using time-resolved luminescence, the probe can detect citrate with high sensitivity and selectivity even in the presence of competing biological anions such as phosphate and bicarbonate, which was validated through detailed spectroscopic studies and computational modelling. The 1:1 binding mode between Eu.1 and citrate was rigorously characterized, providing a clear mechanistic understanding of how the sensor functions at physiological pH. This work establishes rational design principles for next-generation luminescent probes that could enable early, non-invasive monitoring of citrate as a biomarker in cancer and metabolic disease diagnostics.
Dalton transactions (Cambridge, England : 2003)
Source →sPaRT2 - Minimally Invasive Partial versus Radical Nephrectomy for cT2 Renal Cell Carcinoma: A National Matched-Pair Analysis (UroCCR 235).
Et-Touzani R, et al
A new French multicenter study compared robot-assisted partial nephrectomy (RAPN) — a kidney-sparing surgery — with radical nephrectomy (RN), which removes the entire kidney, in patients with large kidney tumors (clinical stage T2 renal cell carcinoma). Using propensity score matching from the national UroCCR database, researchers analyzed 500 patients (250 per group) to determine whether RAPN could match RN's cancer control while better preserving kidney function. The study found that cancer outcomes were statistically equivalent between the two approaches, with five-year disease-free survival of 61% for RAPN versus 49% for RN, and overall survival identical at 80% in both groups. Critically, patients who underwent RAPN experienced significantly better preservation of kidney function over five years, with less chronic kidney disease progression and fewer acute kidney injury episodes, though major surgical complications were modestly higher after RAPN (6% vs. 2%). These findings are important because loss of kidney function after radical nephrectomy can lead to long-term health problems including cardiovascular disease and dialysis dependence, and this study demonstrates that kidney-sparing surgery is a safe and functionally superior option for carefully selected patients treated at expert centers.
The Journal of urology
Source →